PROSTATE CANCER AND HIS INFLUENCE ON REPRODUCTIVE HEALTH
The aim of the study. Based on the data of the National Cancer Registry the research aims at conducting an analysis of morbidity and mortality of the male population of Ukraine for prostate cancer from 2014 to 2019.
Materials and Methods. We have studied the indicators of the proportion of malignant neoplasms of the pelvic organs among the ten main nosological forms of malignant neoplasms in the morbidity of the male population of Ukraine, the proportion of malignant neoplasms of the pelvic organs among the ten major nosological forms of malignant neoplasms in the mortality of male malignancies in Ukraine, mortality from malignant neoplasms of the prostate in Ukraine and the percentage of morphologically and histologically confirmed cases of malignant neoplasms of the prostate in Ukraine in the period from 2014 to 2019.
Results and Discussion. Among the ten main nosological forms of malignant neoplasms in the structure of the incidence of malignant neoplasms in the male population, the share of diseases of malignant neoplasms of the prostate in 2019 is 12.4%. The proportion of malignant neoplasms of the prostate in the mortality structure of the male population of Ukraine from 2014 to 2019 increased from 8.3% to 9.7%, respectively, while the proportion of malignant neoplasms of the rectum and bladder were in some years higher or equal to 2019. The absolute number of cases of malignant neoplasms of the prostate from 2014 to 2019 increased from 6851 cases to 8178 cases, i.e. by 1327 cases, which is 16.23%. Mortality of the male population of Ukraine from malignant neoplasms of the prostate from 2014 to 2019 fluctuated, with an increase in 2017 and a decrease in 2018, but the mortality rate increased from 3119 cases in 2014 to 3323 cases in 2019. The average percentage of morphologically confirmed cases of malignant neoplasms of the prostate was 90.6±0.81%, and the average percentage of histologically confirmed cases of malignant neoplasms of the prostate was 83.57±1.06. Correlation-regression analysis of the growth of the incidence of malignant neoplasms of the prostate in Ukraine for the next 5 years showed that the number of cases will increase significantly but will not exceed 10,000 cases. Correlation-regression analysis of the growth of mortality from malignant neoplasms of the prostate in Ukraine for the next 5 years showed that by 2024 mortality from this pathology will reach almost 3,500 cases per year.
Conclusions. The obtained data indicate a clear trend towards an increase in morbidity and mortality from malignant neoplasms of the prostate. Among the main factors that may influence this are the low level of vaccination of male and female population of Ukraine from highly oncogenic strains of human papillomavirus, lack of motivation of the male population of Ukraine to a comprehensive screening of the prostate after 45 years and low awareness of the need for such screening, availability of three-component vaccines against human papillomavirus on the pharmaceutical market of Ukraine, while vaccination with seven-component vaccines against this virus is routine in the European Union. Further research on the coverage of the male population with vaccination and on the awareness of the male population of Ukraine about the risks of prostate cancer is necessary in terms of preventing reproductive dysfunction and the proper formation of reproductive health in general.
Cancer in Ukraine, 2014-2020. Morbidity, mortality, performance indicators of the oncology service [Electronic resource] / Fedorenko Z.P., Gulak L.O., Mykhailovych Yu.Y. etc. // Bulletin of the National Cancer Registry of Ukraine No. 22. - 2021. - Resource access mode: http://ncru.inf.ua/publications/BULL_22/index.htm. Application date: 01.12.2021. Ukrainian: (Рак в Україні, 2014-2020. Захворюваність, смертність, показники діяльності онкологічної служби [Електронний ресурс] / Федоренко З.П., Гулак Л.О., Михайлович Ю.Й. та ін. // Бюлетень Національного канцер-реєстру України № 22. - 2021. - Режим доступу до ресурсу: http://ncru.inf.ua/publications/BULL_22/index.htm. Дата звернення: 01.12.2021).
Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020 Jan;77(1):38-52. doi: 10.1016/j.eururo.2019.08.005. Epub 2019 Sep 5. PMID: 31493960.
Tikkinen K A O, Dahm P, Lytvyn L, Heen A F, Vernooij R W M, Siemieniuk R A C et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline BMJ 2018; 362 :k3581 doi:10.1136/bmj.k3581
Moyer, Virginia A. "Screening for prostate cancer: US Preventive Services Task Force recommendation statement." Annals of internal medicine 157.2 (2012): 120-134.
Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health 2020; published online Nov 16. DOI:S2214-109X(20)30459-9 https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30459-9/fulltext
Bleyer A, Spreafico F, Barr R. Prostate cancer in young men: An emerging young adult and older adolescent challenge. Cancer. 2020 Jan 1;126(1):46-57. doi: 10.1002/cncr.32498. Epub 2019 Sep 25. PMID: 31553489.
Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014 Sep-Oct;80(5):412-7. doi: 10.1016/j.aogh.2014.09.014. PMID: 25512156.
Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW, Wender RC. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2018 Jul;68(4):297-316. doi: 10.3322/caac.21446. Epub 2018 May 30. PMID: 29846940.
Sadri Nahand J, Esghaei M, Hamidreza Monavari S, Moghoofei M, Jalal Kiani S, Mostafaei S, Mirzaei H, Bokharaei-Salim F. The assessment of a possible link between HPV-mediated inflammation, apoptosis, and angiogenesis in Prostate cancer. Int Immunopharmacol. 2020 Nov;88:106913. doi: 10.1016/j.intimp. 2020.106913. Epub 2020 Sep 1. PMID: 32889239.
Fedewa SA, Ward EM, Brawley O, Jemal A. Recent Patterns of Prostate-Specific Antigen Testing for Prostate Cancer Screening in the United States. JAMA Intern Med. 2017;177(7):1040-1042. doi:10.1001/jamainternmed.2017.0340
Goldenberg, M. G., Skeldon, S. C., Nayan, M., Suppiah, Y., Chow, L., Fryml, E., Greenberg, D., Singal, R. K., & Goldenberg, S. L. (2017). Prostate-specific antigen testing for prostate cancer screening: A national survey of Canadian primary care physicians' opinions and practices. Canadian Urological Association Journal, 11(12), 396-403. https://doi.org/10.5489/cuaj.4486
This work is licensed under a Creative Commons Attribution 4.0 International License.